Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Supplement Article
You have accessRestricted Access

Renal Replacement Therapy in Patients with Diabetes and End-Stage Renal Disease

Francesco Locatelli, Pietro Pozzoni and Lucia Del Vecchio
JASN January 2004, 15 (1 suppl) S25-S29; DOI: https://doi.org/10.1097/01.ASN.0000093239.32602.04
Francesco Locatelli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pietro Pozzoni
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucia Del Vecchio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

ABSTRACT. The number of patients who have diabetes and ESRD and are being admitted to renal replacement treatment (RRT) is increasing dramatically worldwide, and in many countries, diabetes has become the single most frequent cause of ESRD. Although the prognosis of patients who have diabetes and are receiving RRT has greatly improved, survival and medical rehabilitation rates continue to be significantly worse than those of nondiabetic patients, mainly because of preexisting severely compromised cardiovascular conditions. The most common RRT modality in patients with diabetes is still hemodialysis, but it gives rise to a number of clinical problems, in particular difficulties in the management of the vascular access and high frequency of intradialytic hypotension. However, patients who have diabetes and are on peritoneal dialysis have to face a progressive increase in peritoneal permeability, loss of ultrafiltration, and peritoneal fibrosis, all phenomena being accelerated in patients with diabetes and ultimately leading to an increased technique failure. The results of observational studies and national registries, although conflicting, suggest that these two dialytic modalities are somehow comparable in terms of outcomes, whereas accumulating evidence shows that both survival and medical rehabilitation of patients with diabetes are significantly better after renal transplantation, which should be the first-choice option for patients who have diabetes and reach ESRD but unfortunately still accounts for only a limited proportion of RRT treatments in these patients.

The number of patients who have diabetes and ESRD and are being admitted to renal replacement treatments (RRT) is increasing dramatically, to the point that, during the past few years, in many countries, diabetes has or will soon become the most frequent single cause of ESRD. According to the United States Renal Data System (USRDS), the annual number of patients who have diabetes and are admitted to RRT in the United States more than doubled between 1995 and 2000 (from 19,155 to 41,685), and there was a striking increase in the percentage of incident ESRD patients with diabetes as the primary diagnosis (30.4% in 1987, 36.3% in 1992, and 45.2% in 2000) (1). The corresponding figures in other countries are lower (Figure 1) but show similar trends. In Italy, diabetes was the third most frequent known cause of ESRD in incident patients in 2000 (15.9%) after vascular nephropathies (20.6%) and chronic glomerulonephritis (16.7%) (2). In Lombardy, the percentage of patients with diabetes among patients who were newly admitted to RRT increased from 9% in 1983 to 11% in 1992 (3) and reached 17% in 1998. In Japan, this proportion increased from 21.3% in 1986 to 31.9% in 1995 (4).

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. Year 2000 percentages of incident renal replacement treatment patients with diabetes as the primary diagnosis according to national registries.

There are various reasons for the increasing number of patients who have diabetes and are being admitted to RRT. First, as a result of the aging of the population, the prevalence of type 2 diabetes in the general population is increasing worldwide, because type 2 diabetes is a chronic degenerative disease and therefore is becoming more frequent with advancing age (it is forecasted that the number of patients with diabetes worldwide will reach 221 million by 2010, whereas they were 124 million in 1997). Furthermore, the survival of patients with diabetic nephropathy has significantly improved, thus allowing them to live long enough to develop ESRD. Finally, patients with type 2 diabetes, who are usually elderly, are now more readily admitted to RRT than in the past.

As a consequence of the increasing number of patients who have diabetes and are being admitted to RRT and of their improved survival, the prevalence of RRT patients with diabetes has also significantly increased worldwide: in the United States, the proportion of RRT patients with diabetes as the presumed cause of ESRD increased from 26.9% in 1991 to 30.6% in 1995 and to 36% in 2000 (1); in Lombardy, the same proportion increased from 4.6% in 1986 to 7.9% in 1996 and in Madrid from 7.4% in 1985 to 1986 to 12.7% in 1997 to 1998 (5).

RRT Modalities: Impact on Prognosis

Thirty years ago, survival of patients who had diabetes and were on RRT was catastrophic (6). Although it has greatly improved since then, patients with diabetes continue to do significantly worse than nondiabetic patients. According to the USRDS, the adjusted 5-yr survival of patients who have diabetes and started RRT in 1995 was 33.6% (it was 24.5% for patients who started dialysis in 1985), significantly worse than that of patients in whom the primary cause of ESRD was hypertension (42.0%), glomerulonephritis (53.0%), or other renal diseases (43.0%) (1).

The main reason for such a high mortality rate, which is of cardiovascular origin in the majority of cases (7), is that the cardiovascular conditions of patients with diabetes are already severely impaired when they start RRT, as demonstrated by the high prevalence of coronary heart disease, stroke, peripheral occlusive disease, and amputations (8–10⇓⇓). This also explains why patients who have diabetes and are on RRT are at higher risk of developing de novo cardiovascular disease, particularly ischemic heart disease, which not only is more frequent but also has a more aggressive course than in nondiabetic patients (11).

Comparative survival analyses of patients who have diabetes and are on hemodialysis or peritoneal dialysis, although with conflicting results, have shown that the two dialytic modalities are substantially comparable in terms of patient outcome, when considering the whole diabetic population (12–14⇓⇓). The survival rates of patients who have diabetes and are on hemodialysis or peritoneal dialysis are also approximately similar. In the multicenter study by Maiorca et al. (15), 7-yr survival was not significantly different among patients with and without diabetes on the two modalities. According to the Catalonia Registry, 5-yr survival in patients with diabetes was 30% on hemodialysis and 25% on peritoneal dialysis (16). In a study by Locatelli et al. (17) of incident patients who lived in Lombardy, no significant difference was found in cardiovascular mortality or morbidity between patients on hemodialysis or peritoneal dialysis, even when the analysis was limited to patients with diabetes (Figure 2). It therefore can be concluded that there is not any a priori first-choice dialytic treatment modality for patients with diabetes and ESRD, and the decision to adopt hemodialysis or peritoneal dialysis should be made on medical grounds and, above all, on the wishes of the individual patients.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2. Survival of patients who have diabetes and are on hemodialysis and peritoneal dialysis in Lombardy considering cardiovascular mortality and the de novo development of cardiovascular diseases as end points (calculated from reference 17).

However, both survival and medical rehabilitation of patients with diabetes are significantly better after kidney transplantation. USRDS data show that the adjusted 5-yr survival in patients who had diabetes and received a kidney from a cadaveric or a living donor in 1995 was 75.2% and 83.0% respectively, far higher than the 29.2% 5-yr survival of patients who had diabetes and started dialysis in the same year (1). Although the survival of patients with diabetes and a kidney graft is worse than that of their nondiabetic counterparts (1), mainly as a result of a higher prevalence of pretransplantation cardiovascular disease, the gain in life expectancy after renal transplantation is proportionally much higher in patients with diabetes than without: in a retrospective observational study, Wolfe et al. (18) analyzed the reduction in the long-term risk of death achieved in the transplant recipients as compared with patients who remained on the waiting list for transplantation and found that it was greater in the subgroup of patients with diabetes (73%) than in those with glomerulonephritis (61%) or other causes of ESRD (62%). Although a selection bias affecting the patients who received a transplant could not be completely ruled out, these results suggest that renal transplantation should be considered the first-choice option also, and above all, in patients with diabetes.

Hemodialysis

Hemodialysis is still the most common RRT modality in patients with diabetes: in 2000, it was adopted in >80% of prevalent RRT patients with diabetes in Italy (2) and in >75% in the United States (1). The first problem to be faced when choosing hemodialysis for patients with diabetes is the vascular access, because advanced calcific atherosclerosis leads to frequently inadequate arterial inflow and eventually also to venous run-off problems. Indeed, patients with diabetes have worse access survival rates and more steal syndromes and often require a more proximal anastomosis (19,20⇓). For these reasons, the creation of the vascular access must be considered at an earlier stage in patients with diabetes than without, and the first choice must be a native arteriovenous fistula, which leads to more positive outcomes in patients with diabetes when careful attention is given to timely access creation, preoperative evaluations, surgical techniques, and surveillance program (19).

Another major problem for patients who have diabetes and are on maintenance hemodialysis is intradialytic hypotension, which is far more common than in patients without diabetes for a number of reasons, including autonomic dysfunction as a result of polyneuropathy, vascular damage, impaired left ventricular compliance, and the susceptibility of patients with diabetes to overhydration in the interdialytic interval. The high frequency of intradialytic hypotension makes it particularly difficult to reach the targeted dry weights in patients with diabetes, ultimately leading to worse BP control, as documented by the higher proportion of hemodialysis patients with diabetes requiring antihypertensive treatment (50 versus 27.7%) (21). Every effort therefore should be made to avoid the development of intradialytic hypotension in patients with diabetes by discontinuing antihypertensive therapy before dialysis sessions and, when necessary, by prescribing longer dialysis sessions with lower ultrafiltration rates.

Glycemic control is another major objective in hemodialysis patients with diabetes, as the achievement of a satisfactory glycemic control, even after the beginning of hemodialysis, was shown to have a positive impact on morbidity and survival (22). Furthermore, hyperglycemia causes thirst and high fluid intake, as well as an osmotic shift of water and potassium from the intracellular to the extracellular space, thus contributing to circulatory congestion and hyperkalemia. For these reasons, insulin should be administered without reservation also to patients who have diabetes and are on hemodialysis, whereas a dialysate containing glucose at a concentration of 11 mmol/L should be used, because it protects against the development of hypoglycemic and intradialytic hypotensive episodes without affecting glycemic control (23).

Peritoneal Dialysis

Although survival is substantially equivalent in patients who have diabetes and are on hemodialysis or peritoneal dialysis and there may be some good reasons for initially offering peritoneal dialysis to patients with diabetes (including, above all, difficulties in creating a vascular access), only a small proportion of patients with diabetes receive peritoneal dialysis. In Italy, only approximately 10% of the prevalent RRT patients with diabetes in 2000 were receiving peritoneal dialysis (2), and an even smaller percentage (6%) was recorded in the United States in the same year (1). However, wide differences existing between countries suggest that the selection of treatment is more influenced by cultural, logistic, and reimbursement policies than by medical considerations.

The major problems of patients who are on peritoneal dialysis are the progressive increase in peritoneal membrane permeability to small solutes, the loss of ultrafiltration, and the development of peritoneal fibrosis. These phenomena, promoted by severe or recurrent peritonitis and by the use of conventional glucose-containing peritoneal dialysis solutions and ultimately leading to technique failure, seem to be accelerated in patients with diabetes, thus explaining why the risk of technique failure, which is greater in peritoneal dialysis than in hemodialysis patients, is even higher in patients with diabetes than without (24). In this context, the use of nonglucose peritoneal dialysis solutions, such as icodextrin, or those in multichambered bags may be particularly promising.

Transplantation

Although for the reasons mentioned above renal transplantation is the first-choice RRT option for patients who have diabetes and reach ESRD, it unfortunately still accounts for only a limited proportion of RRT treatments in these patients: only 16% of the United States prevalent patients who have diabetes and are on RRT in 2000 received a transplant, the majority of them having type 1 diabetes (1). The situation is even worse in other countries such as Italy, where, in the same year, the percentage of patients who had diabetes and were on RRT and had undergone transplantation was 8.4% among men and 6% among women (2).

A particularly promising strategy for patients with type 1 diabetes and ESRD is simultaneous pancreas and kidney transplantation (SPKT), as suggested by recent observational studies that have indeed reported a significant survival advantage for SPKT recipients with type 1 diabetes over cadaver kidney transplant recipients, whereas the results of the comparison with living donor kidney transplant recipients have not been unequivocal (25,26⇓). Furthermore, it also should be remembered that SPKT improves the quality of life and a number of secondary complications of diabetes, including gastric and bladder function, metabolic impairment, and autonomic polyneuropathy (27,28⇓).

It therefore is clear that renal transplantation, possibly combined with simultaneous pancreas transplantation in patients with type 1 diabetes, should now be the primary objective for all patients who have diabetes and reach ESRD and that every effort should be made to increase the use of this RRT modality in patients with diabetes.

  • © 2004 American Society of Nephrology

References

  1. ↵
    US Renal Data System: 2002 Annual Data Report. Bethesda, MD, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2002
  2. ↵
    Conte F, Salone M: Italian Registry of Dialysis and Transplantation 2000 report. Available at http://www.sin-ridt.org/sin- ridt.org.htm
  3. ↵
    Marcelli D, Spotti D, Conte F, Limido A, Lonati F, Malberti F, Locatelli F: Prognosis of diabetic patients on dialysis: Analysis of Lombardy Registry data. Nephrol Dial Transplant 10: 1895–1900, 1995
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Kikkawa R, Kida Y, Haneda M: Nephropathy in type II diabetes—Epidemiological issues as viewed from Japan. Nephrol Dial Transplant 13: 2743–2745, 1998
    OpenUrlFREE Full Text
  5. ↵
    Perez-Garcia R, Rodriguez Benitez P, Verde E, Valderrabano F: Increasing of renal replacement therapy (RRT) in diabetic patients in Madrid. Nephrol Dial Transplant 14: 2525–2527, 1999
    OpenUrlFREE Full Text
  6. ↵
    Ghavamian M, Gutch CF, Kopp KF, Kolff WH: The sad truth about hemodialysis in diabetic nephropathy. JAMA 222: 1366–1372, 1972
    OpenUrl
  7. ↵
    Koch M, Thomas B, Tschope W, Ritz E: Survival and predictors of death in dialysed diabetic patients. Diabetologia 36: 1113–1117, 1993
    OpenUrlCrossRefPubMed
  8. ↵
    Stack AG, Bloembergen WE: Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: A cross-sectional study. J Am Soc Nephrol 12: 1516–1523, 2001
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Eggers PW, Gohdes D, Pugh J: Nontraumatic lower extremity amputations in the Medicare end-stage renal disease population. Kidney Int 56: 1524–1533, 1999
    OpenUrlCrossRefPubMed
  10. ↵
    Schomig M, Ritz E, Standl E, Allenberg J: The diabetic foot in the dialyzed patient. J Am Soc Nephrol 11: 1153–1159, 2000
    OpenUrlFREE Full Text
  11. ↵
    Herzog CA, Ma JZ, Collins AJ: Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 339: 799–805, 1998
    OpenUrlCrossRefPubMed
  12. ↵
    Fenton SS, Schaubel DE, Desmeules M, Morrison HI, Mao Y, Copleston P, Jeffrey JR, Kjellstrand CM: Hemodialysis versus peritoneal dialysis: A comparison of adjusted mortality rates. Am J Kidney Dis 30: 334–342, 1997
    OpenUrlPubMed
  13. ↵
    Vonesh EF, Moran J: Mortality in end-stage renal disease: A reassessment of differences between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 10: 354–365, 1999
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Collins AJ, Hao W, Xia H, Ebben JP, Everson SE, Costantini EG, Ma JZ: Mortality risks of peritoneal dialysis and hemodialysis. Am J Kidney Dis 34: 1065–1074, 1999
    OpenUrlPubMed
  15. ↵
    Maiorca R, Vonesh EF, Cavalli P, De Vecchi A, Giangrande A, La Greca G, Scarpioni LL, Bragantini L, Cancarini GC, Cantaluppi A: A multicenter, selection-adjusted comparison of patient and technique survivals on CAPD and hemodialysis. Perit Dial Int 11: 118–127, 1991
  16. ↵
    Rodriguez JA, Cleries M, Vela E: Diabetic patients on renal replacement therapy: Analysis of Catalan Registry data. Renal Registry Committee. Nephrol Dial Transplant 12: 2501–2509, 1997
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Locatelli F, Marcelli D, Conte F, D’Amico M, Del Vecchio L, Limido A, Malberti F, Spotti D: Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. J Am Soc Nephrol 12: 2411–2417, 2001
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LYC, Held PJ, Port FK: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341: 1725–1730, 1999,1999
    OpenUrlCrossRefPubMed
  19. ↵
    Konner K, Hulbert-Shearon TE, Roys EC, Port FK: Tailoring the initial vascular access for dialysis patients. Kidney Int 62: 329–338, 2002
    OpenUrlCrossRefPubMed
  20. ↵
    Yeager RA, Moneta GL, Edwards JM, Landry GJ, Taylor LM Jr, McConnell DB, Porter J: Relationship of hemodialysis access to finger gangrene in patients with end-stage renal disease. J Vasc Surg 36: 245–249, 2002
    OpenUrlCrossRefPubMed
  21. ↵
    Ritz E, Strumpf C, Katz F, Wing AJ, Quellhorst E: Hypertension and cardiovascular risk factors in hemodialyzed diabetic patients. Hypertension 7 [Suppl 11]: S118–S124, 1985
    OpenUrl
  22. ↵
    Morioka T, Emoto M, Tabata T, Shoji T, Tahara H, Kishimoto H, Ishimura E, Nishizawa Y: Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 24: 909–913, 2001
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Simic-Ogrizovic S, Backus G, Mayer A, Vienken J, Djukanovic L, Kleophas W: The influence of different glucose concentrations in haemodialysis solutions on metabolism and blood pressure stability in diabetic patients. Int J Artif Organs 24: 863–869, 2001
    OpenUrlPubMed
  24. ↵
    Serkes KD, Blagg CR, Nolph KD, Vonesh EF, Shapiro F: Comparison of patient and technique survival in continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis: A multicenter study. Perit Dial Int 10: 15–19, 1990
  25. ↵
    Becker BN, Brazy PC, Becker YT, Odorico JS, Pintar TJ, Collins BH, Pirsch JD, Leverson GE, Heisey DM, Sollinger HW: Simultaneous pancreas-kidney transplantation reduces excess mortality in type 1 diabetic patients with end-stage renal disease. Kidney Int 57: 2129–2135, 2000
    OpenUrlCrossRefPubMed
  26. ↵
    Reddy KS, Stablein D, Taranto S, Stratta RJ, Johnston TD, Waid TH, McKeown JW, Lucas BA, Ranjan D: Long-term survival following simultaneous kidney-pancreas transplantation versus kidney transplantation alone in patients with type 1 diabetes mellitus and renal failure. Am J Kidney Dis 41: 464–470, 2003
    OpenUrlCrossRefPubMed
  27. ↵
    Matas AJ, McHugh L, Payne WD, Wrenshall LE, Dunn DL, Gruessner RW, Sutherland DE, Najarian JS: Long-term quality of life after kidney and simultaneous pancreas-kidney transplantation. Clin Transplant 12: 233–242, 1998
    OpenUrlPubMed
  28. ↵
    Navarro X, Sutherland DER, Kennedy WR: Long-term effects of pancreatic transplantation on diabetic neuropathy. Ann Neurol 42: 727–736, 1997
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 15 (1 suppl)
Journal of the American Society of Nephrology
Vol. 15, Issue 1 suppl
1 Jan 2004
  • Table of Contents
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Renal Replacement Therapy in Patients with Diabetes and End-Stage Renal Disease
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Renal Replacement Therapy in Patients with Diabetes and End-Stage Renal Disease
Francesco Locatelli, Pietro Pozzoni, Lucia Del Vecchio
JASN Jan 2004, 15 (1 suppl) S25-S29; DOI: 10.1097/01.ASN.0000093239.32602.04

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Renal Replacement Therapy in Patients with Diabetes and End-Stage Renal Disease
Francesco Locatelli, Pietro Pozzoni, Lucia Del Vecchio
JASN Jan 2004, 15 (1 suppl) S25-S29; DOI: 10.1097/01.ASN.0000093239.32602.04
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • RRT Modalities: Impact on Prognosis
    • Hemodialysis
    • Peritoneal Dialysis
    • Transplantation
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Cardiovascular and Renal Risk Assessment as a Guide for Treatment in Primary Hypertension
  • Increased Sodium-Lithium Countertransport Activity: A Cellular Dysfunction Common to Essential Hypertension and Diabetic Nephropathy
  • Hypertensive Renal Damage in Metabolic Syndrome Is Associated with Glucose Metabolism Disturbances
Show more Supplement Article

Cited By...

  • Fetuin-A aggravates lipotoxicity in podocytes via interleukin-1 signaling
  • Spatial Analysis of Case-Mix and Dialysis Modality Associations
  • Differential effects of Smad3 targeting in a murine model of chronic kidney disease
  • LONG-TERM MODALITY-RELATED MORTALITY ANALYSIS IN INCIDENT DIALYSIS PATIENTS
  • Plasma Connective Tissue Growth Factor Is an Independent Predictor of End-Stage Renal Disease and Mortality in Type 1 Diabetic Nephropathy
  • Incidences, Treatments, Outcomes, and Sex Effect on Survival in Patients With End-Stage Renal Disease by Diabetes Status in Australia and New Zealand (1991 2005)
  • CAN WE OVERCOME THE PREDESTINED POOR SURVIVAL OF DIABETIC PATIENTS? PERSPECTIVES FROM PRE- AND POST-DIALYSIS
  • The Pathogenesis of Myocardial Fibrosis in the Setting of Diabetic Cardiomyopathy
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire